Skip to content

Prevalence of Non Celiac Gluten Sensitivity Among Patients Spontaneously Adherent to Gluten Free Diet

Prospective, Randomized, Double-blind, Placebo-controlled Clinical Trial With a Cross-over Design to Assess the Prevalence of Non Celiac Gluten Sensitivity Among Patients Spontaneously Adherent to Gluten Free Diet

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01827566
Enrollment
26
Registered
2013-04-09
Start date
2012-07-31
Completion date
Unknown
Last updated
2014-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non Celiac Gluten Sensitivity

Keywords

Celiac Disease, Gluten Sensitivity, Gluten, Double-blind challenge, placebo-controlled challenge, Gluten free flour

Brief summary

The purpose of this study is to assess the prevalence of Gluten Sensitivity, by a double-blind placebo-controlled challenge with gluten, followed by two months period of Low-FODMAPs (Fermentable Oligosaccharides Disaccharides Monosaccharides And Polyols) diet, in patients spontaneously adherent to gluten free diet because of symptoms upon gluten exposure and in whom diagnosis of Celiac Disease and Wheat Allergy has been ruled out.

Interventions

OTHERgluten

Sponsors

Università degli Studi di Brescia
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
DIAGNOSTIC
Masking
DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Adherence to gluten free diet without medical need * Negative Celiac Disease related serology (while on gluten containing diet) * Normal villous structure at duodenal biopsy (while on gluten containing diet)

Exclusion criteria

* Diagnosis of Celiac Disease * Diagnosis of Wheat Allergy * Diagnosis of organic gastrointestinal disease * Severe concomitant disease

Design outcomes

Primary

MeasureTime frameDescription
Patient's ability to correctly identify the phase with glutenTime (days) 35* time 0: start of first challenge (phase A, either with gluten or gluten free flour) * time 10: end of phase A and start of wash-out period * time 25: end of wash-out period and start of second challenge (phase B, either with gluten or gluten free flour) * time 35: end of phase B

Secondary

MeasureTime frameDescription
Changes in serum level of anti-tissue transglutaminases immunoglobulin A (IgA)/immunoglobulin G (IgG) and of anti-gliadin IgA/IgGTime (days) 0, 10, 25, 35* time 0: start of first challenge (phase A, either with gluten or gluten free flour) * time 10: end of phase A and start of wash-out period * time 25: end of wash-out period and start of second challenge (phase B, either with gluten or gluten free flour) * time 35: end of phase B
Change in Fatigue Visual ScaleTime (days) 0, 10, 25, 35* time 0: start of first challenge (phase A, either with gluten or gluten free flour) * time 10: end of phase A and start of wash-out period * time 25: end of wash-out period and start of second challenge (phase B, either with gluten or gluten free flour) * time 35: end of phase B
Change in Gastrointestinal Rating Score (GSRS) during Challenge with and without glutenTime (days) 0,10, 25, 35* Time 0: Start of first challenge (phase A, either with gluten or gluten free flour) * Time 10: end of phase A and start of wash-out period * Time 25: end of wash-out period and start of second challenge (phase B, either with gluten or gluten free flour) * Time 35: end of phase B * At the beginning of Low-FODMAPs diet * After two months of Low-FODMAPs diet
Change in symptoms' score (1 to 7 Likert scale) as recorded on a daily diaryFrom Time 0 (days) to 10 and from 25 to 35* time 0: start of first challenge (phase A, either with gluten or gluten free flour) * time 10: end of phase A and start of wash-out period * time 25: end of wash-out period and start of second challenge (phase B, either with gluten or gluten free flour) * time 35: end of phase B

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026